TransCode Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
RNAZ Nasdaq 2836 www.transcodetherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for TransCode Therapeutics, Inc.

TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up - Sep 28th, 2026 6:04 am
TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology - Sep 22nd, 2026 6:04 am
Join Today's Live Investor Webinar with TransCode Therapeutics - Sep 16th, 2026 7:00 am
TransCode Therapeutics Announces Leadership Transition - Sep 10th, 2026 2:10 pm
Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer - Sep 3rd, 2026 7:00 am
TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis - Aug 31st, 2026 6:05 am
Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV - Aug 7th, 2026 7:00 am
TransCode Therapeutics to Host R&D Webcast on June 18, 2026 - Jun 8th, 2026 6:04 am
RNAZ: Introducing RNA Therapeutics - Jun 8th, 2026 3:27 am
TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer - Jun 3rd, 2026 6:04 am
EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study - Jun 3rd, 2026 5:41 am
TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University - Apr 27th, 2026 6:02 am
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028 - Apr 7th, 2026 6:30 am
CK Life Sciences Establishes Sequencio Therapeutics to Advance Therapeutic Cancer Vaccines Development - Mar 10th, 2026 6:21 am
TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development - Feb 23rd, 2026 6:01 am
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 - Feb 5th, 2026 6:04 am